GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apellis Pharmaceuticals Inc (NAS:APLS) » Definitions » Cyclically Adjusted Book per Share

APLS (Apellis Pharmaceuticals) Cyclically Adjusted Book per Share : $1.64 (As of Mar. 2025)


View and export this data going back to 2017. Start your Free Trial

What is Apellis Pharmaceuticals Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Apellis Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2025 was $1.307. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $1.64 for the trailing ten years ended in Mar. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2025-05-13), Apellis Pharmaceuticals's current stock price is $17.28. Apellis Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $1.64. Apellis Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 10.54.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Apellis Pharmaceuticals was 21.45. The lowest was 10.69. And the median was 17.59.


Apellis Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

The historical data trend for Apellis Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apellis Pharmaceuticals Cyclically Adjusted Book per Share Chart

Apellis Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 1.56

Apellis Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 1.56 1.64

Competitive Comparison of Apellis Pharmaceuticals's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Apellis Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apellis Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Apellis Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Apellis Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


;
;

Apellis Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Apellis Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book= Book Value per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=1.307/134.9266*134.9266
=1.307

Current CPI (Mar. 2025) = 134.9266.

Apellis Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201409 0.000 100.428 0.000
201412 -1.251 99.070 -1.704
201506 -1.636 100.684 -2.192
201509 -1.882 100.392 -2.529
201512 -2.333 99.792 -3.154
201609 0.000 101.861 0.000
201612 -3.773 101.863 -4.998
201703 0.000 102.862 0.000
201706 0.623 103.349 0.813
201709 -2.584 104.136 -3.348
201712 2.959 104.011 3.839
201803 2.559 105.290 3.279
201806 4.088 106.317 5.188
201809 3.484 106.507 4.414
201812 2.860 105.998 3.641
201903 3.555 107.251 4.472
201906 2.499 108.070 3.120
201909 2.185 108.329 2.721
201912 0.535 108.420 0.666
202003 3.435 108.902 4.256
202006 3.070 108.767 3.808
202009 1.398 109.815 1.718
202012 2.687 109.897 3.299
202103 0.642 111.754 0.775
202106 -1.748 114.631 -2.057
202109 -0.657 115.734 -0.766
202112 2.037 117.630 2.337
202203 4.343 121.301 4.831
202206 3.130 125.017 3.378
202209 2.783 125.227 2.999
202212 1.534 125.222 1.653
202303 3.547 127.348 3.758
202306 2.938 128.729 3.079
202309 1.962 129.860 2.039
202312 1.627 129.419 1.696
202403 2.199 131.776 2.252
202406 2.172 132.554 2.211
202409 1.943 133.029 1.971
202412 1.836 133.157 1.860
202503 1.307 134.927 1.307

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Apellis Pharmaceuticals  (NAS:APLS) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Apellis Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=17.28/1.64
=10.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Apellis Pharmaceuticals was 21.45. The lowest was 10.69. And the median was 17.59.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Apellis Pharmaceuticals Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Apellis Pharmaceuticals's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Apellis Pharmaceuticals Business Description

Traded in Other Exchanges
Address
100 Fifth Avenue, Waltham, MA, USA, 02451
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
Executives
James George Chopas officer: See Remarks 950 WINTER STREET, WALTHAM MA 02451
David O. Watson officer: General Counsel 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Mark Jeffrey Delong officer: Senior Vice President 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
Adam J. Townsend officer: See Remarks C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Pascal Deschatelets officer: Chief Operating Officer 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Karen Lewis officer: Chief People Officer APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
Jeffrey Eisele officer: See Remarks APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
Nur Nicholson officer: Chief Technical Officer APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
Timothy Eugene Sullivan officer: Chief Financial Officer 800 BOYLSTON ST., SUITE 3310, PRUDENTIAL TOWER C/O AJU IB INVESTMENT, BOSTON MA 02199
Cedric Francois director, 10 percent owner, officer: Chief Executive Officer 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Caroline Baumal officer: Chief Medical Officer C/O APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
A. Sinclair Dunlop director C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Lukas Scheibler officer: See Remarks C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Alec Machiels director 505 PARK AVENUE, 21ST FLOOR, NEW YORK NY 10022
Federico Grossi officer: See Remarks C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014